Why questions test completeness
A quote arrives as a total, and a total looks finished. Founders eager to move forward can mistake that finished look for completeness and commit on the strength of a number whose contents they have never examined. The five questions in this guide break that spell. Each probes a place where a partial quote hides its gaps: work included in one quote and billed separately in another, a fee that may or may not be credited, a second run that may or may not be affordable, money leaving earlier than expected, and goods arriving later than planned. A complete quote answers all five clearly; a partial quote answers some, evades others, or answers in generalities that cannot be checked.
The questions expand five questions in the skincare line cost guide, which lists them in short form. Only two published bands are referenced here, and only as the amounts the questions are about: the testing band and the development band. Every other part of the quote is discussed in terms of scope and clarity, not figures, because the job of these questions is to establish what is included, not to price what is missing. Pricing comes from quotes on a comparable basis; completeness comes from questions asked before commitment. Ask the same five questions of every manufacturer, in the same words, and keep the answers side by side. A manufacturer who answers clearly will welcome the comparison, because clear answers compare well.
Which tests are included?
The first question asks for the test list: which testing items are included in the quoted figure, named item by item, for each formula in the launch. It is not asking for reassurance that testing is covered — reassurance is easy to give and hard to check, while a list is easy to check. The list should name the items, state which formula each applies to, and make clear whether the quoted figure covers the whole list or only part of it. A founder who receives a list can compare it with lists from other manufacturers and see where scopes differ. A founder who receives only a general statement has nothing to compare, and will discover the gaps only when a separate charge appears later.
What is billed separately?
The second question is the companion to the first. If the first asks what is included, the second asks what is not — and what the separate charges are for, and on what basis they will be billed. It asks the manufacturer to draw the boundary of the quote in plain terms, so the founder can see the full cost of the launch rather than only the part fitting neatly into a total. Separate billing is not in itself a problem; many manufacturers bill certain items separately for sensible reasons, and a separately billed item can be perfectly fair. The problem is separate billing never mentioned until after commitment, when the founder has no choice but to accept it. Asking now turns a future surprise into a present fact.
The launch total is the quote plus everything billed separately, and a founder planning only around the quote will under-budget. Testing items billed separately are the commonest example, and the testing band of $500–$3,000 per formula is the right frame for judging them: a separately billed item should be stated on the same basis, per formula, so it can be added to the quote and compared fairly. Separate billing can also apply to additional sample rounds, changes to packaging, or work arising from a change in the brief. A clear answer names each separately billed item, states the basis on which it will be charged, explains what triggers it, and distinguishes items that will certainly be charged from items that may be charged, and optional items from necessary ones. Ask for that list in writing, alongside the included list.
Is the development fee credited?
The third question concerns custom formulation: whether any development fee is credited against the first order. Development fees are usually billed separately from the production run, and the published development band is $2,000–$15,000+ per formula. The credit question asks whether that fee, in whole or in part, is deducted from the cost of the first production run, or stands entirely separate as a sunk cost of development. A fee fully credited is, in effect, a deposit on production; a fee not credited at all is an additional cost on top of production. Both arrangements exist and both can be fair. What is not fair is leaving the founder to guess which applies.
Reorder minimums and payment terms
The fourth question asks two things that belong together, because both concern money after the first run: what the reorder minimums are, and what the payment terms are. Reorder minimums are the smallest run the manufacturer will do when you reorder, and the second run usually carries the same minimums as the first, so the founder must be able to fund a second run of the same size before the first has sold out, or face a gap in stock. Payment terms are when money is due, in what portions, and on what triggers. A deposit-and-balance structure means a substantial portion leaves before production, with the balance due before shipment, so the founder funds the launch well before the first sale. Knowing both in advance lets the founder plan the cash for the second run and the gap before the first sale, rather than discovering either when it is too late to adjust gracefully.
A clear answer states the reorder minimum per product, in the same terms as the first-run minimum, so the two can be compared directly. It states the payment structure — what portion is due at what stage, and what triggers each portion — in plain terms, without jargon. It states whether the terms for reorders differ from those for the first run, and what happens if a payment is late or an order is changed after it is placed, because those are the moments when unclear terms become costly. Get both parts in writing, as part of the quote or as a written summary alongside it. A quote stating the total but not the terms is a partial quote, however attractive the total looks.
Realistic lead time
The fifth question asks for the realistic lead time from approved samples to shipped goods: how long, in the manufacturer's honest judgement, the sequence will take once samples are approved. It is not asking for the fastest possible time, or a date chosen to win the business. It is asking for the time the manufacturer would plan around if the founder were already a client. A fastest-possible time is a promise made under pressure that rarely survives contact with the real sequence — production scheduling, packaging supply, filling, checks, and shipment each take their place and each can slip. A realistic time is a plan, built on actual capacity and the actual work involved. Ask for the realistic time, and ask what it assumes: that samples are approved without further revision, that packaging is available, that the production slot is held.
Lead time sets every other date in the launch: a launch date, a retail window, a seasonal moment, and the founder's own cash plan all hang from it. If it is understated, every dependent date slips and the founder discovers the slip too late to adjust gracefully; if overstated, the founder may delay a launch that could have proceeded. A clear answer sets out the sequence stage by stage, with the time each stage is expected to take and the total that results, names the assumptions behind the total, and names the events that would extend it, such as a further sample revision or a packaging delay. It distinguishes time the manufacturer controls from time depending on the founder, such as approval times. Given in writing, alongside the quote, it is a commitment the founder can plan against and hold the manufacturer to fairly.
What clear and evasive answers signal
Clear answers are specific, written, and checkable: they name items, state figures on a stated basis, and distinguish what is included from what is billed separately, without requiring the founder to infer or take a verbal assurance on trust. Evasive answers are general, verbal, and uncheckable: they reassure without specifying and treat a request for detail as a lack of trust. Founders sometimes hesitate to press for clarity, fearing they will offend a manufacturer. That fear is misplaced — good manufacturers expect detailed questions from serious founders and answer them readily, because detailed questions show the founder intends to commit on the basis of understanding, not a total. Evasiveness is rarely about a single answer; it is a pattern, and the pattern is the signal. Weigh it alongside the other evidence: responsiveness, sample quality, and the fit described in the guide to choosing a skincare manufacturer, which covers vetting the vendor as a whole. The five questions test quote completeness; the vendor guide tests the vendor. A founder needs both.
Asking before you commit
Ask the questions early, in writing, and all together. Early, because the answers shape the comparison between manufacturers, and a comparison made without them will have to be remade. In writing, because written answers can be kept, compared, and relied upon, while verbal answers fade and shift. All together, because the five questions form a set, and asked together they show the founder is systematic and give the manufacturer a single coherent request to respond to. Keep the answers with the quotes, in the same file, so the record is complete, and compare answers as well as totals: which manufacturer gave the clearest testing list, credit position, terms, and lead time? Clarity is a strong tie-breaker, because it predicts how the relationship will feel when real decisions must be made quickly. Commit only when every question has an answer you can point to, in writing, and when the answers together describe a launch you understand and can fund.